Stock Analysis
Legend Biotech Corporation (LEGN) Stock Analysis
Legend Biotech Corporation (LEGN) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Legend Biotech Corporation (LEGN) currently has an AIQ Score of 59/100, indicating a neutral setup. Momentum is the strongest factor at 80/100. Risk is the weakest current factor at 45/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
LEGN at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $21.63 |
| AIQ Score | 59/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | Strong Buy |
| Market Cap | $3.91B |
| P/E Ratio (TTM) | -42.26 |
| Forward P/E | — |
| EPS (quarter ended 2026-06-30) | $0.18 |
| Revenue (quarter ended 2026-06-30) | $387.5M |
| Dividend Yield (TTM) | 0.00% |
| Beta | 0.39 |
| Volume | 2.19M |
| 52-week range | $16.24-$37.50 |
| RSI 14 | 70.04 |
| 50-Day SMA | $19.55 |
| 200-Day SMA | $22.14 |
| Analyst Price Target | $56.29 |
| Next Earnings | Nov 10, 2026 |
LEGNLegend Biotech Corporation
Healthcare / Biotechnology
Low Priority
Above Peers
Latest quote
- Momentum80
- Value54
- Quality52
- Risk resilience45
- Sentiment—
LEGN Stock Analysis Summary
Legend Biotech Corporation (LEGN) currently has an AIQ Score of 59/100, indicating a neutral setup. Momentum is the strongest factor at 80/100. Risk resilience is the weakest current factor at 45/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, LEGN has AIQ Score of 59/100 with Momentum base of 80/100 and fading Risk resilience at 45/100. Wait for component alignment before adding exposure.
Momentum (80/100) leads while Risk resilience (45/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · -3.00% stock move · LEGN classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is LEGN Bullish or Bearish Right Now?
LEGN currently has a neutral overall setup. Momentum is the strongest factor at 80/100, while Risk Resilience is weakest at 45/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Momentum is constructive at 80/100.
- - Price is +14.09% above its 50-day SMA.
- - Analyst target implies +160.24% upside from the latest quote.
- - Technical consensus has more buy votes than sell votes (35 vs 9).
- - No strong bearish evidence is available in the current snapshot.
Current Consensus
LEGN's Technical Analysis Consensus is currently Strong Buy, with 35 buy, 1 neutral, and 9 sell votes. LEGN's 14-day RSI is 70.04, which places the stock in an overbought momentum range. LEGN's beta is 0.39, indicating lower market sensitivity than the broad market.
What Changed in LEGN?
The largest recent change in LEGN is Momentum moving up by 36.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.
What Would Change the LEGN Outlook?
The current neutral outlook could improve if AIQ moves above 70, momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 40, price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ > 70, RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 40, RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
LEGN Decision Framework
Public evidence layers, setup checks, and risk context for Legend Biotech Corporation.
Legend Biotech Corporation (LEGN) Stock Analysis
Legend Biotech Corporation has an AIQ Score of 59/100 in a Neutral regime. Momentum is strongest at 80/100. Beta is 0.4, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | LEGN is in a Neutral AIQ regime with score 59/100. |
| Signal Conflict | The primary conflict is that momentum leads at 80/100 while risk lags at 45/100. |
| Factor Evidence | Momentum 80/100 · Value 54/100 · Quality 52/100 · Risk 45/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Momentum is the strongest factor at 80/100.
Momentum is 80/100 and RSI (14) is 70.0.
LEGN is in a Neutral regime at 59/100.
Risk factor is 45/100 with beta 0.4 and annual volatility 75.68%.
Current conflict: momentum leads at 80/100 while risk lags at 45/100.
LEGN Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
LEGN Fundamentals
LEGN valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
LEGN Technical Analysis
LEGN technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
LEGN Stock Catalysts
Track LEGN earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
LEGN Dividend Analysis
LEGN dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
LEGN Financial Data
LEGN revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
LEGN Risk Analysis
LEGN volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
LEGN Stock News
LEGN stock news, market tone, recent headlines, and catalyst context.
LEGN vs Gene Editing / Genomics / Biotech Peers
Current peer cohort: LEGN · MRVI · NTLA · NUVB · PRMB. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| LEGN Current stock | 59/100 | 54/100 | 80/100 | 45/100 | -0.18 | 75.68% | Current |
| MRVI Maravai LifeSciences | 45/100 | 34/100 | 72/100 | 46/100 | 1.75 | 69.10% | LEGN vs MRVI |
| NTLA Intellia Therapeutics | 41/100 | 34/100 | 64/100 | 42/100 | 0.36 | 79.70% | LEGN vs NTLA |
| NUVB Nuvation Bio | 39/100 | 34/100 | 36/100 | 43/100 | 0.22 | 82.00% | LEGN vs NUVB |
| PRMB Preimmune | 39/100 | 49/100 | 45/100 | 49/100 | -0.03 | 49.34% | LEGN vs PRMB |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Oct 29, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Oct 31, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Jun 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching LEGN
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for LEGN
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
LEGN Stock FAQ
What is LEGN stock price today?
Legend Biotech Corporation's current stock price is $21.63. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is LEGN bullish or bearish right now?
LEGN's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is LEGN's market cap?
LEGN's market cap is $3.91B based on the latest completed market-close snapshot from Oct 30, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is LEGN's current P/E ratio?
LEGN's current P/E ratio is -42.26 based on the latest completed market-close snapshot from Oct 30, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is LEGN's RSI?
LEGN's 14-day RSI is 70.04 based on the latest completed market-close snapshot from Oct 30, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is LEGN above its 50-day and 200-day moving averages?
LEGN is 14.09% from its 50-day SMA and 0.71% from its 200-day SMA based on the latest completed market-close snapshot from Oct 30, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is LEGN's next earnings date?
LEGN's next earnings date is currently listed as Nov 10, 2026. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does LEGN pay a dividend?
LEGN's dividend yield is 0.00% based on the latest completed market-close snapshot from Oct 30, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.